Algernon Pharmaceuticals Inc., of Vancouver, British Columbia, said it priced its marketed public offering of a minimum of about 22.7 million units and a maximum of 45.5 million units priced at 11 cents per unit for gross proceeds of $2.5 million to $5 million.